NDC product
Triple Antibiotic
NDC 11673-892 · Target Corporation
Key facts
| Product NDC | 11673-892 |
|---|---|
| Proprietary name | Triple Antibiotic |
| Nonproprietary name | bacitracin zinc, neomycin sulfate, and polymyxin b sulfate |
| Substances | BACITRACIN ZINC, POLYMYXIN B SULFATE, NEOMYCIN SULFATE |
| Dosage form | OINTMENT |
| Route | TOPICAL |
| Labeler | Target Corporation |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M004 |
| Pharmacologic classes | Aminoglycoside Antibacterial [EPC], Aminoglycosides [CS], Decreased Cell Wall Synthesis & Repair [PE], Polymyxin-class Antibacterial [EPC], Polymyxins [CS] |
| Marketing start | Jan 31, 2024 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: